parsaclisib   Click here for help

GtoPdb Ligand ID: 10098

Synonyms: compound 20 [PMID: 31749910] | IBI376 | INCB-050465
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Parsaclisib (INCB050465) is a PI3Kδ inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [1]. The chemical structure is one of those claimed in patent WO2013033569A1, but it was not immediately clear which example it was from a mixture of diastereoisomers 345-348 (347 and 348 had the highest inhibitory potency vs. PI3Kδ and 347 was tested in vivo) [2]. The 2019 disclosure by Yue et al. confirmed the structure as patent example 346 [4]. Preclinical and phase 1/2 clinical evidence suggests that compared to first-generation PI3Kδ inhibitors, parsaclisib has reduced hepatotoxicity [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 107.95
Molecular weight 432.15
XLogP 2.88
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOc1c(C2CNC(=O)C2)c(F)c(cc1[C@@H](n1nc(c2c1ncnc2N)C)C)Cl
Isomeric SMILES CCOc1c(C2CNC(=O)C2)c(F)c(cc1[C@@H](n1nc(c2c1ncnc2N)C)C)Cl
InChI InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11?/m0/s1
No information available.
Summary of Clinical Use Click here for help
Parsaclisib (INCB50465) has advanced to Phase 2 clinical trial. It is being evaluated in multiple studies looking at its efficacy in various lymphomas and B cell malignancies, and in Sjögren's syndrome and autoimmune hemolytic anemia. NCT04142554 will evaluate parsaclisib in patients with triple negative or HER2+ breast cancers. Click here to link to's full list of INCB50465 trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Parsaclisib's antitumour mechanism involves targeting PI3Kδ-mediated proliferative signalling in malignant B cells and inhibiting Treg immunosuppression in the tumour microenvironment [3-4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03627065 A Study of INCB050465 in Primary Sjögren's Syndrome Phase 2 Interventional Incyte Corporation
NCT03538041 A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Phase 2 Interventional Incyte Corporation
NCT02718300 A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Phase 2 Interventional Incyte Corporation
NCT03235544 A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) Phase 2 Interventional Incyte Corporation